Abeona Therapeutics(NASDAQ) ABEO

Abeona makes medicine that fixes the root cause of rare skin and eye diseases. Their main product helps heal painful wounds in children and adults with a severe skin condition. They use advanced technology to deliver healthy genes directly into a patient's cells.

What Does Abeona Make?

• ZEVASKYN: Surgical gene-modified skin sheets used to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
• Ophthalmic Therapies: Experimental treatments for rare eye diseases, including X-linked Retinoschisis (XLRS) and Stargardt disease, which cause vision loss.
• AIM Vector Platform: Technology that uses modified viruses to carry healthy genetic material into specific parts of the human body.
• Licensed Programs: Gene therapy projects for conditions like Sanfilippo syndrome and Rett syndrome managed by external partners.

Growing the Gene Therapy Pipeline

• Sold a Priority Review Voucher to a third party in June 2025 for $155 million in gross proceeds.
• Partnered with Beacon Therapeutics in July 2024 to use AAV204 technology for eye disease treatments.
• Licensed clinical programs to Ultragenyx Pharmaceutical Inc. and Taysha Gene Therapies, Inc. to earn potential milestones and royalties.
• Activated four specialized treatment centers by March 2026 to deliver skin therapy to patients across the United States.

Why the Company Stands Out

Abeona operates its own large-scale manufacturing facility in Cleveland, Ohio, which gives the company full control over production. This internal setup is designed to speed up the delivery of medicines while maintaining high quality standards for cell therapies.

Tracking the Recent Financials

• Revenue grew to $5.4 million in Q4 2025, up from zero in Q4 2024 as commercial sales began.
• Gross profit reached $1.7 million in Q4 2025, an improvement of 321.6% compared to a loss the previous year.
• Net loss deepened to $20.5 million in Q4 2025, a 120.2% increase in losses from $9.3 million in Q4 2024.
• Market capitalization rose to $279.1 million in Q4 2025, up 22.1% from $228.6 million in Q4 2024.

A Transition to Commercial Stage

Abeona has successfully moved from a research-focused organization to a commercial drug maker following its first product approval. Its ownership of specialized manufacturing and partnerships with other biotechs provide a foundation for managing rare genetic conditions.